

## **Press Release**

Stockholm, 3 April 2009

### **Change in Biovitrum's Nomination Committee**

After Investor AB's acquisition of shares in Biovitrum AB during March, decision has been made regarding a change in the current Nomination Committee. Charlotte Munthe Nilsson, Investor AB, has been appointed new member of the Nomination Committee. Investor AB is the largest shareholder in Biovitrum AB and represents according to the announcement (March, 27th, 2009) 10,697,307 shares in Biovitrum, which corresponds to 21.4 per cent of the share capital and 21.5 per cent of the votes in the company.

With reference to the above the representative of Nordic Capital, Henrik Lif, has left the Nomination Committee.

The Annual General Meeting will be held in Stockholm on 28 April 2009.

#### **For further information please contact:**

Martin Nicklasson, CEO  
Phone: +46 8 697 25 45

Göran Arvidson, CFO  
Cell phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations  
Cell phone: +46 73 422 15 40  
[erik.kinnman@biovitrum.com](mailto:erik.kinnman@biovitrum.com)

#### **About Biovitrum**

Biovitrum is a Swedish pharmaceutical company. The company markets a range of specialist pharmaceuticals internationally. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases and malabsorption. The company has revenues of approximately SEK 1.1 billion and around 400 employees. It is listed on the OMX Nordic Exchange in Stockholm. For more information go to [www.biovitrum.com](http://www.biovitrum.com).